Prostate cancer is usually a slow-growing carcinoma (cancer of epithelium / lining) in the prostate
gland. Cancer typically forms in
the prostate's glandular tissue, doubling in size every 4-5 years, but sometimes
it is in the prostate muscle and connective tissue. Initially cancer cells
are confined to the prostate, present no symptoms and cause no harm, but in time
they can metastasize (usually to bones or lymph nodes), at which time symptoms present
and the risk of dying is significantly increased. That said, a man may have PC without
even being aware of it - and in fact, almost 75% of men over 80 yrs who die of other
causes have PC.
Some types of PC can be more aggressive - presenting symptoms
earlier than usual that may require treatment.
Prostate enlargement (Benign Prostate
Hyperplasia or BPH - a major cause of problems in older men) may be associated
with prostate cancer.
Key statistics about prostate cancer
Prostate cancer is the second-most
commonly diagnosed cancer in American men (after skin
cancer)
1 man in 7 will be diagnosed with prostate cancer during his lifetime
- about 220,800 new cases in U.S. in 2015 (American
Cancer Society data)
Prostate cancer is the second
leading cause of cancer DEATH
in American men - lung cancer is #1;
About 1 man in 38 will die of prostate cancer
- About 27,540 deaths in U.S. in 2015
(American Cancer Society data)
Probability of getting prostate cancer increases with age
- mostly affecting males over age 50. About 6 out
of 10 cases diagnosed are in men aged 65 or older, and it is rare before age 40.
The average age at the time of diagnosis is about 66.
Prostate cancer incidence and mortality rates are significantly
higher in the Western world
compared to Asian populations - suggesting
a possible dietary / environmental link. (statistics are age-standardized
to give a better comparison since PC is predominant in older men). In 2022, PC incidence rate of prostate cancer in U.S., UK, EU and
Australia was ~75-80
per 100,000 compared to ~10 per 100,000 in China. In 2022 in the U.S. there was
a 9.7% risk of prostate cancer at age 74, compared to 1.1% in China.
Prostate Cancer Rates by Country 2025 In 2022,
the death rate for prostate cancer was8.1 per 100,000 in the
U.S., compared to 3.3 per 100,000 in China. The UK was 11.8 per 100,000 and
Nigeria was 27.9 per 100,000!
Prostate cancer statistics | World Cancer Research Fund
Prostate cancer detection
Usually detected by a high Prostate Specific Antigen
(PSA) count
(although there are other tests more indicative
of prostate cancer and its progress) - the PSA count is higher when the immune system
is dealing with a prostate problem. A slightly raised PSA count could simply be
due to an infection / inflammation of the prostate. A normal PSA level is less
than 4 ng / mL of blood. 4-10 ng / mL suggests possible BPH or prostate cancer
(in 25% of men), over 10 ng / mL is associated with prostate cancer (in
50% of men). Men in their 50's or younger typically have a PSA around 2.5 ng /
mL.
PSA readings have no upper limit and can reach 10,000 ng / mL or more.
Ultra-scans and prostate biopsies. Cancer tumors are typically found here and there
throughout the prostate, and not as a single prostate cancer mass.
Semen / Seminal Fluid
Right and left seminal vesicles attach to the prostate secrete seminal
fluid. This drains into the prostate and urethra via the ejaculatory
ducts. Semen is alkaline to help neutralize acidity in the vaginal tract
Semen (ejaculated during orgasm) is formed from:
Prostatic Fluid (25-30% / from prostate) -during ejaculation, muscular contractions
squeeze prostatic fluid into urethra (whose other function is to carry urine
from bladder out through penis)
Seminal fluid (65-75% /from seminal vesicles) -excretory duct of each of
two seminal glands (located in pelvis) opens into the vas deferens to enter
the part of urethra passing through the prostate gland; high in fructose, it
can provide food for the sperm on their journey
Sperm (2-5% / from testes) - travel via the vas deferens from testes
to join with the seminal vesicle to form the ejaculatory duct, which passes
through the prostate and empties into the urethra. Rhythmic muscle movements
propel sperm forward during ejaculation. After a vasectomy, ejaculate
no longer contains sperm.
Bulbourethral fluid (<1% / bulbourethral glands) -its cohesive jelly-like
texture "hangs on to"sperm and lessens semen viscosity allowing them to
swim in it more easily
Prostate cancer symptoms
Overlapping symptoms of prostate enlargement (benign prostate
hyperplasia / BPH) and prostate cancer sometimes make it difficult to distinguish
between the two:
Urgent need to urinate
Excessive urge to urinate throughout the day
Difficulty urinating or the need to force out urine
Weak urination or dribbles
Urine flow that stops and starts
Feeling like your bladder never fully empties
However, there are some distinct symptoms signifying prostate cancer
vs. BPH:
Burning when urinating
Painful ejaculation
Blood in urine or semen
Erectile dysfunction
Lower amounts of ejaculate
Pelvic area discomfort
Infertility
Prostate cancer causes / factors
Age. Your risk of prostate cancer increases as you age.
Obesity. Waist circumference / belly fat increases your risk
of dying early. Each 4 in.of waist size increases the chance of developing fatal
PC by 18% and a premature death from any cause by 11%., according to an Oxford university
study (published in 2020) involving 140,000 men, mean age 52 years, across 8 countries.
The study also found that obesity increased the risk of getting a high-grade
(aggressive form) of PC by 13%. University
of Oxford Study published in the British Medical Journal, 2020
Genetics
Race.
For reasons not yet determined, black men carry a greater risk of
prostate cancer than do men of other races. Black / non-Hispanic
men rates per 100, 000 men reported 176 incidences / 38 deaths, white non-Hispanic
men 105 incidences / 18 deaths. In black men, prostate cancer is also more likely
to be aggressive or advanced.
Asian societies have a lower incidence of invasive prostate cancer.
Also, associated mortality is lower than in Western society
Family history. If men in your family have had prostate cancer,
your risk may be increased. Also, if you have a family history of genes that increase
the risk of breast cancer (BRCA1 or BRCA2) or a very strong family history of breast
cancer, your risk of prostate cancer may be higher. Familial prostate cancer
occurs in about 10% of cases - occurring at an earlier age than non- familal
prostate cancer. World Health Organization: Cancers of the
male reproductive tract. In World Cancer Report, Stewart BW and Kleihues P (eds).
Lyon, France: IARC Press, 2003, pp 208- 211.
Fat intake. Urinary concentrations of
androgens and estrogens
decreased in a group of white and black men who had decreased their dietary
fat intake.74
Magnesium Deficiency / Calcium Excess
Calcium and magnesium are opposites in their effects on our body
structure. As a general rule, the more rigid and inflexible our body
structure is, the less calcium and the more magnesium we need.
High calcium supplements increase PC risk. A 1998 Harvard's
Health Professionals follow-up study of 47,750 men found those consuming between
1,500 and 1,999 mg of calcium supplements
per day had about double the risk of being diagnosed with metastatic prostate
cancer as those getting 500 mg per day or less. And those taking in 2,000 mg
or more had over four times the risk of developing metastatic prostate cancer
as those taking in less than 500 mg. The Harvard scientists speculated that
the problem is a relative lack of active vitamin D (CALCITRIOL), rather than
the calcium itself. A prospective
study of calcium intake and incident and fatal prostate cancer, Feb 2006
High intake of protein or calcium from dairy productsassociated with an increased risk of PC.
An increase of 35g / day of dairy protein (milk products,
cheese, yogurt) is associated with a 32% increased risk of PC. Calcium
from from dairy products was also associated with higher PC risk, but not from
other foods.
Univ.
of Oxford study published 2008 in BJ of Cancer.,
Systematic review of studies suggest a link between prostate cancer
and milk consumption.Sargsyan A, Dubasi HB.
Milk Consumption and Prostate Cancer: A Systematic Review. World J Mens Health.
2021 Jul;39(3):419-428. doi: 10.5534/wjmh.200051. Epub 2020 Jul 27. PMID: 32777868;
PMCID: PMC8255404. PubMed
Sex hormone imbalance
Sex hormones have a significant role in PC initiation and promotion
The main hormones involved in prostate cancer
testosterone
DHT
estradiol
progesterone
Mainstream medicine focuses on high level testosterone as the main culprit in PC.
However, there is a lack of credible evidence from many studies looking
for a correlation between testosterone levels
and PC occurrence;
If testosterone were the cause of prostate
cancer, we’d see 19 and 20 year old males (with their raging
testosterone levels) developing PC.
and it is typically a disease seen in older men. That said,
testosterone must also be present for prostate
cancer to occur.
testosterone actually prevents
estradiol from causing PC by destroying the
PC cells it stimulates.
Androgen deprivation treatment
(ADT) decreases life
expectancy due to causing heart disease:
DHT is more the problem thantestosterone
Males produceprogesterone
(~ 1/2 the amount of women) which prevents the body's conversion of
testosterone to DHT by
inhibiting the enzyme 5-alpha reductase (even
more effectively than Proscar and Saw Palmetto - the often-used agents used in traditional
and natural medicine).
All cells (except brain and muscle cells) multiply
continuously, with cell growth regulated by the p53 and bcl- 2 genes
If the oncogene bcl2 dominates - it will push cells
towards becoming cancerous.
If the p53 gene dominates - cellular replication
is controlled and the cancer does not occur.
One way to cure cancer is to find agents that activate p53 and
deactivate bcl- 2:
Hormones:
estradiol
Turns ON the cancer gene BCL2 whereas
progesterone turns ON the
anti-cancer gene p53
Dr. John R. Lee (a pioneer of natural hormone therapy) hypothesizes that estrogen
dominance over testosterone is a more probable
cause than high testosterone levels - referencing
estrogen dominance as the only known cause of uterine cancer (where, in women,
estrogen
is dominant over progesterone), he mentions that both the uterus and prostate develop
from the same embryonic cells, and both contain the oncogene BCL- 2 (B- cell lymphoma
2), and the cancer protective gene P53
estradiol increases cell proliferation,
progesterone decreases it
P53 gene "tells" cell to die on time by promoting its apoptosis
(or natural cell death) and can also stop DNA-damaged cells from dividing.
If p53 gene dominates, the products of this gene activation promote healthy
apoptosis, and thus control cell growth, such that cancer does not occur.
progesterone "turns on" P53 - allowing
apoptosis of cancer cells
Breast cancer cells do not multiply when women are on
progesterone - which also reverses cancer
of the ovary and uterus and small cell lung cancer (normally having a dismal
diagnosis).
Bcl- 2 gene blocks the p53 cancer- protective gene. If Bcl-
2 dominates, cell growth increases, i.e. cells become cancerous.
estradiolhas been shown to "turn
off" p53 gene, consequently ending its blocking of Bcl- 2 - thus allowing
cancer cell development in both breast and prostate cells.
"To die or not to die?", JAMA. Jan. 28, 1998; 279:300- 307
In 1997, Dr.T.S. Wiley and Dr. Ben Formby (a Danish molecular biologist)
grew cell cultures of breast, endometrium, ovary and prostate. Adding
estradiol turned on the Bcl- 2 gene resulting in cells growing rapidly and
not dying. By next adding progesterone, the cells
stopped growing as rapidly, died on time and the cancer disappeared.
1997, Dr.T.S. Wiley and Dr. Ben Formby, U. of California, Santa
Barbara
To summarize - Contrary to mainstream belief, it is the
estrogenestradiol
that causes prostate cancer, not
testosterone.
In men, if the estradiol to
testosterone ratio changes to cause a dominance
of estradiol, prostate cancer cells can develop.
However, testosterone must also be present for
prostate cancer to occur. progesterone supplementation
is an obvious treatment for men with
testosterone
deficiency relative to their estradiol levels.
Men make estradiol, although in much lower
amounts than women.
Study examined local aromatase enzyme expression
and estrogen biosynthesis in the human prostate
and demonstrated local estrogen biosynthesis
in prostate malignancy, via prostate- induced aromatase
gene expression. Also, the study showed potential alteration of aromatase promoter
use with progression of disease. In NON- malignant prostate tissues, aromatase
mRNA expression was absent from epithelium, but did localize to stroma.
Ellem SJ et al,
Local Aromatase
Expression in Human Prostate Is Altered in Malignancy, 2004, J Clin Endocrinol
Metab 89: 2434- 2441.
A high level of estrogen metabolite 4- hydroxyestrone
(4- OHE1) in a man's body might increase his risk of developing prostate cancer
- one conclusion from a 2010 study offers another novel finding . . . that high
levels of estrogen metabolites (16- KE2 and 17-
epiE3), considered fuel for breast cancer, might offer a protective benefit
against prostate cancer - The relative amounts of the 15 estrogens and estrogen
metabolites in the urine of prostate cancer cases were similar to that of non-cancer patients with the exception of the following estrogen metabolites:
(a) 4- OHE1 were more abundant in men WITH prostate cancer and
(b) 16- KE2 and 17- epiE3 were more abundant in those WITHOUT prostate cancer
ScienceDaily,
Apr. 22, 2010
Higher levels of estradiol have been found in men who have enlarged prostate
glands
Estrogen and androgens must BOTH be present to produce cancer in the prostate
(according to a
study
using mice). Androgens (e.g. testosterone, DHT) must be present, but are not necessarily
the cause of prostate cancer; the study demonstrated:
Estrogen (without
androgens) showed direct proliferative response, characterized
by discrete lobe-specific changes including smooth-muscle regression, fibroblast
proliferation, inflammation, and basal epithelial cell proliferation and metaplasia.
Lifetime exposure to elevated androgen exposure developed prostatic hyperplasia, but no malignant changes in prostate;
Combinedandrogen and estrogen treatment has been shown to induce BOTH prostatic
dysplasia (development of abnormal cells) and PC (adenocarcinoma).
G P Risbridger, J J Bianco, S J Ellem and S J McPherson, Oestrogens
and prostate cancer, Endocrine- Related Cancer (2003) 10 187- 191
PubMed
Prostate enlargement is a major cause of problems in elderly men.
progesterone levels decrease with
age (beginning around age 35 in women and 45 in men). As
progesterone levels decrease, the male's
5- alpha reductase converts the
testosterone to DHT
which is ineffective at removing PC cells that
estradiol
stimulates.
Estrogen dominance is likely the
problem. It has been clearly established that estrogen accumulates
in the aging prostate gland concurrent with its enlargement, leading to difficult
urination and frequent urination
Estradiol stimulates the enlargement
of the prostate. This allows the prostate gland to swell and enlarge
and in many cases transform into prostate cancer. The prostate is embryologically
similar to the female uterus. Krieg M, Nass R, Tunn S. Effect
of aging on endogenous level of 5 alphadihydrotestosterone, testosterone,
estradiol,
and estrone in epithelium and stroma of normal and hyperplastic human prostate.
J Clin Endocrinol Metab. 1993; 77: 375- 381.
DISCLAIMER: The content on this website is intended for
informational, and educational purposes only and not as a substitute
for the medical advice, treatment or diagnosis of a licensed health
professional. The author of this website is a researcher, not a
health professional, and shall in no event be held liable to any
party for any direct, indirect, special, incidental, punitive or
other damages arising from any use of the content of this website.
Any references to health benefits of specifically named products
on this site are this website author's sole opinion and are not
approved or supported by their manufacturers or distributors.